Led · Series C · Nov 2025

Aspen Neuroscience is pioneering personalized regenerative medicine by converting a patient’s own skin cells into induced pluripotent stem cells and then into dopaminergic neuronal precursor cells to treat neurodegenerative diseases. Its lead candidate, ANPD001, is the most advanced autologous cell therapy in the U.S. for moderate to advanced Parkinson’s disease and has received FDA Fast Track designation. The company’s proprietary manufacturing platform integrates machine-learning-based genomic testing for rigorous quality control and scalability, and it includes a precision MRI-guided delivery device for minimally invasive transplantation. Recent clinical progress includes initiation of Cohort 3 in a Phase 1/2a trial, with earlier cohorts showing favorable safety and clinician- and patient-reported improvements without the need for immunosuppression. Aspen plans to expand its pipeline to additional neurological indications while scaling manufacturing to meet future commercial demand. Headquartered in San Diego, the private company has raised more than $340 million to date, including an $8 million grant from the California Institute for Regenerative Medicine.

Participated · Equity · Feb 2025

VitalConnect is a leader in biosensor technology focused on ambulatory cardiac monitoring. Its proprietary biosensor streams eight vital signs and biometric parameters live over a seven-day wear period. The company leverages biomedical engineering, data analytics, chip design, and mobile and cloud software to support clinical decision making and better health and economic outcomes. Its products are designed for use in both remote and in‑patient settings to deliver lower‑cost care and greater convenience for patients and providers. Four years after its commercial launch, VitalConnect reports commercial growth and plans to expand its commercial presence. The company closed $100 million in financing (equity and debt) to accelerate that expansion. VitalConnect develops wearable biosensors and a cloud/mobile platform (the VitalPatch) for real-time remote and in-hospital monitoring. The company leverages biomedical engineering, data analytics, chip design and software to support clinical decision-making and lower healthcare costs. VitalConnect has deployed hundreds of thousands of biosensors globally at institutions including Brigham and Women’s, Hackensack Medical Center, Northwell Health and John Radcliffe Hospital‑Oxford University. The new funding will support a rapidly growing remote cardiac monitoring business and help advance partnerships with the largest U.S. hospital systems to provide remote patient monitoring in inpatient settings. VitalConnect reports revenue tripled from 2021 to 2022, is on track to nearly double revenue again in 2023, has seen significant EBITDA improvement, and expects to achieve profitability in 2024. VitalConnect is a leader in wearable biosensor technology, offering the VitalPatch for real-time remote and in-hospital monitoring. Founded in 2011 and based in San Jose, Calif., the company combines biomedical engineering, data analytics, chip design, and mobile and cloud software to support clinical decision-making. Its devices have deployed hundreds of thousands of biosensors worldwide and are used in care facilities including Brigham and Women's, Hackensack Medical Center, Northwell Health, and John Radcliffe Hospital–Oxford University. Products target a broad range of inpatient and outpatient use cases such as hospital monitoring, post-discharge care, cardiac monitoring, and pharmaceutical solutions. VitalConnect reports strong physician adoption and growth over the past 18 months since launch. The company plans to use new funding to accelerate its cardiac monitoring business and advance remote patient monitoring for heart failure, COPD, sepsis, and other conditions, strengthening commercial access to patients and providers. VitalConnect’s flagship product, the VitalPatch, enables real-time remote and in-hospital patient monitoring. The company combines biomedical engineering, data analytics, chip design, and mobile and cloud software to support clinician decision-making. VitalConnect has deployed more than 200,000 patches worldwide and is used at institutions including Brigham and Women’s, Hackensack Medical Center, Northwell Health, and John Radcliffe Hospital–Oxford University. The company announced a $39 million growth financing to expand its commercial team, scale operations, and develop new products to drive top-line growth. The round was funded by EW Healthcare Partners alongside other new and existing investors, and EW Operating Partner Robert S. White joined VitalConnect’s board. VitalConnect’s products target inpatient and outpatient settings such as hospital monitoring, post-discharge care, cardiac monitoring, and pharmaceutical solutions. VitalConnect develops the VitalPatch wearable biosensor and a software platform for wireless patient monitoring in hospitals and remote settings. The VitalPatch is a small, single-use Class II FDA-approved, band-aid-like device that continuously measures eight vital signs in real time. The company's software platform is already being implemented in select hospitals. Led by founder and CEO Nersi Nazari and launched in 2011, VitalConnect is focused on product development and broader clinical rollout. The company plans to use new funding to continue product development and to roll out the VitalConnect Platform and VitalPatch across hospitals and outpatient settings nationwide. The company has completed multiple funding rounds prior to the current Series C.

Participated · Series C · Mar 2024

Nouscom is a clinical-stage immuno-oncology company based in Basel, Switzerland, developing next-generation off-the-shelf and personalized cancer immunotherapies. Its proprietary viral vector platform can encode large neoantigen payloads and has been clinically demonstrated to safely and potently engage the immune system. Lead programs include NOUS-209 (an off-the-shelf vaccine being evaluated in randomized Phase 2 trials with pembrolizumab for MSI solid tumors and a Phase 1b monotherapy study in Lynch Syndrome) and NOUS-PEV (a personalized cancer immunotherapy expected to enter randomized Phase 2 trials). The company has clinical collaborations and supply agreements with MSD for pembrolizumab and with the National Cancer Institute for Lynch Syndrome studies. Nouscom has also out-licensed VAC-85135, which is under evaluation in a Phase 1 trial sponsored by Janssen and Bristol Myers Squibb. The recently extended Series C financing will fund advancement of its wholly owned clinical pipeline toward multiple clinical proof-of-concept endpoints. NousCom develops neoantigen-based cancer vaccines via its Exovax platform, a viral vector–based genetic vaccine approach using proprietary prime/boost technology to encode large numbers of neoantigens. The company’s lead program, NOUS-209, is an off-the-shelf cancer vaccine planned for Phase I/II clinical studies in 2018 and is being developed both prophylactically for Lynch Syndrome carriers and therapeutically for microsatellite instability (MSI) tumors. A second program, NOUS-100-PV, is a personalized neoantigen vaccine expected to enter clinical studies in the second half of 2018. A third program, an oncolytic virus based on the Endovax platform, remains in discovery. NousCom says its vectors induce potent CD8 and CD4 responses and that it has access to a scalable GMP manufacturing facility to support clinical development and personalized vaccine delivery. The company was founded in 2015 and is headquartered in Basel, Switzerland, with operations in Rome, Italy. Nouscom, based in Basel, Switzerland and Rome, Italy, develops viral vectors, tumor‑selective oncolytic viruses and personalized cancer vaccines. Its pipeline includes two programs: Endovax, an antigenless oncolytic‑vaccine platform, and Exovax, a personalized vaccine encoding patient‑specific neoantigen strings. Endovax uses oncolytic viruses that infect and replicate only in cancer cells, causing immunogenic cell death to recruit and reactivate T cells in the tumor microenvironment. Exovax is based on viral vectors coding for strings of cancer neoantigens to induce and expand patient‑specific T cells. The company will use the €12M Series A to fund discovery and development activities for its personalized vaccine and tumor‑selective oncolytic virus programs. Leadership includes CEO and President Riccardo Cortese, M.D., Ph.D., and a founding scientific team including Alfredo Nicosia, Elisa Scarselli, Stefano Colloca, Antonella Folgori and Cinzia Traboni.

Led · Series D · Feb 2024

SPR Therapeutics is a medical device company focused on providing non-opioid, minimally invasive pain treatments. Its core product, the SPRINT® PNS System, is a 60-day peripheral nerve stimulation therapy cleared for use up to 60 days and studied for low back, shoulder, post-amputation, and post-operative pain. The system is intended to recondition the central nervous system to deliver sustained pain relief without a permanent implant, nerve destruction, or risk of addiction. The device is indicated for symptomatic relief of chronic, intractable pain and various post-surgical and post-traumatic acute pains, but is not intended for cranial and facial nerve regions. Following an $85M financing (a $25M Series D-1 insider equity and a $60M debt facility), SPR plans to use proceeds to expand U.S. sales representation into additional territories and to support continued product development. The company is led by President, CEO and Founder Maria Bennett and is headquartered in Cleveland, OH with satellite offices in Chapel Hill, NC and Minneapolis, MN. SPR Therapeutics commercializes the FDA-cleared SPRINT® Peripheral Nerve Stimulation (PNS) System, a restorative 60-day treatment designed to provide significant and sustained pain relief without permanent implants, nerve destruction, or opioids. The SPRINT system is positioned for early use in the care continuum and has been studied for low back, shoulder, knee, post-operative, and post-amputation neuropathic pain. SPR says clinical trials and more than 30 peer-reviewed publications demonstrate improvements in pain, function, quality of life, and reduced opioid use. The company reports rapid commercial uptake — use more than doubled in the past year and the system has treated over 6,500 patients. SPR also holds over 200 issued and pending patents and emphasizes a large body of clinical evidence underpinning its offering. Headquartered in Cleveland, OH, with satellite offices in Chapel Hill, NC and Minneapolis, MN, SPR plans to expand commercial reach, support additional clinical research, and advance next-generation technology backed by new financing. SPR Therapeutics, based in Cleveland, Ohio, develops neurostimulation technologies for chronic and acute pain. Its FDA-cleared SPRINT® Peripheral Nerve Stimulation (PNS) system uses a threadlike wire placed through the skin connected to a wearable stimulator to activate target nerve fibers, offering a non-narcotic alternative without permanent implants or tissue destruction. The company plans to use the Series C proceeds to commercialize the SPRINT PNS system and to fund additional research across multiple indications, including post-surgical acute pain and chronic low back pain. SPR is led by founder, CEO and president Maria Bennett. The board recently added Nick Valeriani, an experienced healthcare leader who previously served as CEO of West Health and held executive roles at Johnson & Johnson. Prior to this round, SPR had approximately $10 million in prior equity financing and has received nearly $23 million in non-dilutive funding from the U.S. Department of Defense and the National Institutes of Health. SPR Therapeutics has developed a proprietary peripheral nerve stimulation technology platform aimed at treating acute and chronic joint pain and post-amputation pain. Its investigational SPR™ System positions electrodes in proximity to, but not directly contacting, peripheral nerves and is limited by U.S. law to investigational use. The platform includes two products: the SMARTPATCH™ system, intended for use up to 30 days, and the fully implantable MICROPULSE® system for long-term pain management if pain returns after Smartpatch therapy. The company plans to use new funding to commercialize its pain therapies built on this technology. SPR was founded in January 2010 as a portfolio company of NDI Medical, LLC and is led by President and CEO Maria Bennett. The company raised $5m in Series A financing to support those commercialization efforts. SPR Therapeutics makes a generator-based neurostimulation system that electrically stimulates a peripheral nerve to exercise a muscle and treat pain. The system is initially aimed at reducing shoulder pain in patients who have suffered strokes. Company leadership frames the device as a platform technology that could be applied to treat pain in multiple areas of the body. SPR has applied for the CE Mark and may receive European regulatory approval soon. Financially, SPR raised a $2.2 million Series A earlier in the year and has been approved for a $900,000 loan from the Ohio Department of Development to commercialize the technology and fund machinery, molds, tooling, and IP protection costs.

Participated · Series B · May 2023

Carrum Health provides surgical and cancer treatment guidance and coordination for self-funded employers through a Centers of Excellence network that offers all-inclusive pricing and a 30-day warranty. Members pay a fee for access to the network and care coordination. The company launched an oncology offering in partnership with Memorial Sloan Kettering Cancer Center and University of Chicago Medicine after the 2021 investment. Carrum reports a revenue compound annual growth rate of 90%–100% over the last three years and nearly doubled its book of business in 2022. It added six new partners including CVS, Included Health, Accolade, Rightway, SWORD Health and Virgin Pulse and says demand has surged in 2023. The company plans to invest aggressively in its oncology solution and continue expanding its core surgical offering. Carrum Health operates a platform that connects employer-sponsored insurance plans with surgical centers of excellence. It uses machine learning to collect and analyze data on surgical outcomes and care to identify centers of excellence across the U.S. The company offers self-insured employers bundled surgical pricing with no co-pays, deductibles or co-insurance; customers pay a fee and receive a 30-day warranty covering costs from complications or botched operations. Using Carrum can yield savings of up to 50% on surgical expenses, and employees access a mobile app providing virtual care before, during and after surgeries. Named customers include Quest Diagnostics and US Foods, and participating centers of excellence include Johns Hopkins HealthCare, Mayo Clinic and Tenet Healthcare. Carrum plans to expand its reach and add additional services in 2021; it raised $40 million in Series A funding to support sales and marketing, product expansion, and technology improvements. Carrum Health is a comprehensive bundled payment platform that connects self-insured employers to regional healthcare providers through standard bundled payment arrangements. Founded in 2014 and led by CEO Sachin Jain, the company operates from San Francisco and currently serves more than 400 employer groups on the U.S. West Coast. The platform manages acute care bundles intended to control costs and coordinate care for employers and employees. Carrum plans to expand its offering by adding additional acute care bundles in orthopedics, spine and cardiac care and by adding service lines such as bariatrics and maternity. The company will use new funding to enhance its technology and operations platform and to improve analytical insight capabilities.